The ornithine transcarbamylase deficiency market reached a value of USD 689.1 Million across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 1,044.7 Million by 2035, exhibiting a growth rate (CAGR) of 3.86% during 2025-2035.